Event overview and why it matters for BioMarin Pharmaceutical investors
BioMarin Pharmaceutical (BMRN) has scheduled a conference call and webcast for November 2, 2026. President and CEO Alexander Hardy will review third quarter results and provide a general business update.
BioMarin Pharmaceutical shares have eased in recent months, with a 30 day share price return of down 8.15% and a 90 day move of down 9.81%, even though the 1 year total shareholder return is positive at 3.48%. This pattern suggests shorter term momentum has faded ahead of the upcoming results call, while longer term investors have seen mixed outcomes, including a 3 year total shareholder return of down 32.04% and a 5 year total shareholder return of down 33.39%.
Compare BioMarin Pharmaceutical with a hand picked group of rare disease and specialty healthcare players by scanning the 34 healthcare AI stocks that are already on investor watchlists.
BioMarin Pharmaceutical now trades well below where it did a few months ago, despite mixed long term returns. Does that reset leave the risk reward skewed toward buyers, or does it argue for more patience instead?
Most Popular Narrative: 24% Undervalued
BioMarin Pharmaceutical last closed at $55.35, while the most followed narrative on the stock pegs fair value at $73.10. That gap frames the upcoming call as a key test of whether the long term thesis still holds, according to PKU.
Business: focus on enzyme replacement therapies for ultra-rare genetic diseases, special medical knowledge, few patients/limited sales potential per drug globally (no blockbusters), established world wide distribution, complex production, orphan drugs patent protection
The Amicus Therapeutics end 2025 acquisition has understandable strategic fit and adds two US- and EU-approved rare-disease therapies, accretive after closing, commitment to deleveraging
See why 1 investors see BioMarin Pharmaceutical as 24% undervalued.
On PKU's numbers, that $73.10 fair value reflects assumptions such as 15% revenue growth, a 15% profit margin, a future P/E of 22, and a 9% discount rate. The narrative effectively argues that BioMarin Pharmaceutical earns its valuation through deep expertise in ultra rare conditions, complex manufacturing and orphan drug protections, all in markets where patients often remain on treatment for many years.
The same thesis leans on durable barriers to entry and pricing power, helped by specialized medical knowledge, established global distribution and therapies that target conditions with limited alternatives. Long timeframes for treatment, combined with additional therapies from the Amicus Therapeutics acquisition, frame BioMarin Pharmaceutical as a rare disease platform rather than a single product bet.
Result: Fair Value of $73.10 (UNDERVALUED)
Still, the BioMarin Pharmaceutical thesis depends on continued success in ultra rare disease R&D, as well as on regulators and payers supporting premium orphan-drug pricing.
Find out about the key risks to this BioMarin Pharmaceutical narrative.
Another view on BioMarin Pharmaceutical's valuation
The SWS DCF model values BioMarin Pharmaceutical at $225.26 per share, which is far above the current $55.35 price and implies a very wide undervaluation. That sits uncomfortably next to a P/E of 146.8x versus an 18.6x industry average and a 34.1x fair ratio. Is this a rare bargain or a signal that cash flow assumptions need a reality check?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed signals around BioMarin Pharmaceutical can feel confusing. Consider reviewing the full picture for yourself, then weigh the 2 key rewards and 4 important warning signs.
Looking for more BioMarin Pharmaceutical sized investment ideas?
You already know the story with BioMarin Pharmaceutical. Do not stop there when a broader watchlist could highlight opportunities your current portfolio completely misses.
- Spot potential turnaround stories early by scanning the 7 elite penny stocks with strong financials that pair tiny market caps with stronger financial profiles than their prices suggest.
- Zero in on quality at a discount by reviewing the 29 high quality undervalued stocks that combine solid fundamentals with valuations that look out of sync with their underlying strength.
- Prioritise staying power in rough markets by focusing on a 30 resilient stocks with low risk scores that filters for resilient balance sheets and lower risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com